Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them

Abstract

Cervical cancer remains a leading cause of cancer death in women, and outcomes in recurrent or metastatic disease remain poor despite chemoradiation and bevacizumab. The HPV-driven biology that defines the disease—viral E6/E7 oncoproteins, an inflamed microenvironment and exploitable surface antigens—has enabled a rapid expansion of novel systemic therapies, yet existing reviews tend to catalogue these agents by class or report individual trials in isolation, leaving their comparative efficacy, safety and clinical positioning unresolved. Here we organise emerging anti-tumour agents by mechanism of action and array them along a translational maturity gradient, from approved regimens through phase 1/2 candidates to preclinical assets, appraising efficacy and safety in parallel. We cover immune checkpoint inhibitors, bispecific antibodies, antibody–drug conjugates (ADCs), therapeutic HPV vaccines and adoptive cell therapy, and integrate China-developed agents—including the PD-1/CTLA-4 bispecific cadonilimab and the Nectin-4 conjugate 9MW2821—into the global landscape. Departing from a purely descriptive account, we compare class-specific toxicity profiles and predictive biomarkers side by side and, most importantly, translate the fragmented evidence into a resistance-directed treatment framework anchored on platinum-resistant disease. We further argue that, because access to newly approved agents varies widely between health systems, the line of therapy at which an agent is introduced—rather than its approval status alone—may influence survival, a decision-relevant question that current guidelines leave unanswered. This mechanism-based, decision-oriented synthesis is intended to guide rational agent selection, sequencing and combination strategy across diverse clinical settings.